FORMULATION AND EVALUATION OF NANOPARTICLES CONTAINING ANTI-COVID DRUGS FORCONTROLLED DRUG RELEASE

27^th International Congress on Pharmaceutical Biotechnology Research

June 23-24, 2025 Webinar

Abhishek S, Ekshitha G, Rajkiran K

Department of Pharmaceutics, Sri Sivani College of Pharmacy, India

Scientific Tracks Abstracts: Pharm Regul Aff

Abstract :

Favipiravir belongs to Biopharmaceutics ClassificationSystemClassIdrugthathashighersolubilityandhigher permeability. Thedrug needs to be administeredfrequently(2-3timesaday)total1800mgdrug/dayandalsohave shorter half life it means the drugis eliminatingfromthebodyin2-4.5hrs.Thepresentstudywastoovercomethehalflife of favipiravir . So, it is formulated intonano-particleswerepreparedusingahydrophobicpolymer-ethylcelluloseby modified solvent evaporationtechnique.Optimizedformulationwasselectedandpreparedintoatabletformulations using different excipients whichcontrolthedrugrelease.Thefavipiravirloadednanoparticlesweresentto(FT-IR)studies and it shown the absence ofinteractionsofdrugwithotherexcipientsandalsootherstudieslikeDSC,SEM.Attheendof the 10th hour, F1-F6formulationsreleased84.71%–96.43%ofthedrug.AmongalltheformulationsF6waschosenasa best formulation and usedtoprepareavariouscontrolledreleasetablets.Basedonmanyevaluationstudies,thebest tablet formulation was chosen. The invitro dissolution drugreleaseofdrugwascontrolledoverextendedperiodoftimewhichwasaffectedbythe polymer and its amountof polymer.Keywords: Nanoparticles , favipiravir , Ethyl cellulose, controlled release, covid -19.

Biography :

S.Abhishek has his own experience in valuation and passion for ML and data. The research team built this model after many years ofexperience in research, evaluation, work in both hospitals and scientific laboratories. This approach meets all the requirements forprecise, specific, sensitive diagnostics.